Abstract 107 Table 1
EmpagliflozinPlaceboHR (95% CI) p-value for interaction
CV death or HHFn/N (I/100PY)n/N (I/100PY)
LVEF <50%
LVEF ≥50%
145/995 (7.2)
270/2002 (6.7)
193/988 (10.0)
318/2003 (8.0)
0.71 (0.57, 0.88)
0.83 (0.71, 0.98)
0.27
HHF (first and recurrent) Total events/N Total events/N HR (95% CI)
LVEF <50%
LVEF ≥50%
122/995
285/2002
209/988
332/2003
0.57 (0.42, 0.79)
0.83 (0.66, 1.04)
0.06
KCCQ CSS Mean adj. Δ at 52 weeks (SE) Mean adj. Δ at 52 weeks (SE) Mean diff vs placebo at week 52 (95% CI)
LVEF <50%
LVEF ≥50%
4.86 (0.54)
4.24 (0.38)
3.30 (0.55)
2.78 (0.38)
1.56 (0.05, 3.06) 1.46 (0.42, 2.51) 0.92
NYHA class N analysed N analysed OR of lower NYHA class at week 52 (95%CI)
LVEF <50%
LVEF ≥50%
883
1806
869
1814
1.43 (1.14, 1.80)
1.34 (1.14, 1.58)
0.64